Presentation is loading. Please wait.

Presentation is loading. Please wait.

Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non–small cell lung cancer: A propensity-matched analysis  Whitney S. Brandt, MD, Wanpu.

Published byYuliani Hartanto Modified over 5 years ago

Similar presentations

Presentation on theme: "Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non–small cell lung cancer: A propensity-matched analysis  Whitney S. Brandt, MD, Wanpu."— Presentation transcript:

1 Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non–small cell lung cancer: A propensity-matched analysis  Whitney S. Brandt, MD, Wanpu Yan, MD, Jian Zhou, MD, Kay See Tan, PhD, Joseph Montecalvo, MD, Bernard J. Park, MD, Prasad S. Adusumilli, MD, James Huang, MD, Matthew J. Bott, MD, Valerie W. Rusch, MD, Daniela Molena, MD, William D. Travis, MD, Mark G. Kris, MD, Jamie E. Chaft, MD, David R. Jones, MD  The Journal of Thoracic and Cardiovascular Surgery  Volume 157, Issue 2, Pages e3 (February 2019) DOI: /j.jtcvs Copyright © 2018 The American Association for Thoracic Surgery Terms and Conditions

2 Figure 1 CONSORT diagram. NSCLC, Non–small cell lung cancer; PET, positron emission tomography. The Journal of Thoracic and Cardiovascular Surgery  , e3DOI: ( /j.jtcvs ) Copyright © 2018 The American Association for Thoracic Surgery Terms and Conditions

3 Figure 2 Five-year DFS (A) and OS (B) for the neoadjuvant versus adjuvant group using the propensity-matched cohort. Chemo, Chemotherapy; DFS, disease-free survival; CI, confidence interval; OS, overall survival. The Journal of Thoracic and Cardiovascular Surgery  , e3DOI: ( /j.jtcvs ) Copyright © 2018 The American Association for Thoracic Surgery Terms and Conditions

4 Figure 3 Five-year DFS and OS by RECIST response (A, B), MPR (C, D), and ypStage (E, F). PD, Progressive disease; SD, stable disease; PR, partial response; CR, complete response; DFS, disease-free survival; CI, confidence interval; OS, overall survival; path, pathologic; MPR, major pathologic response. The Journal of Thoracic and Cardiovascular Surgery  , e3DOI: ( /j.jtcvs ) Copyright © 2018 The American Association for Thoracic Surgery Terms and Conditions

5 Figure 3 Five-year DFS and OS by RECIST response (A, B), MPR (C, D), and ypStage (E, F). PD, Progressive disease; SD, stable disease; PR, partial response; CR, complete response; DFS, disease-free survival; CI, confidence interval; OS, overall survival; path, pathologic; MPR, major pathologic response. The Journal of Thoracic and Cardiovascular Surgery  , e3DOI: ( /j.jtcvs ) Copyright © 2018 The American Association for Thoracic Surgery Terms and Conditions

6 Five-year DFS for the NC versus AC group.
The Journal of Thoracic and Cardiovascular Surgery  , e3DOI: ( /j.jtcvs ) Copyright © 2018 The American Association for Thoracic Surgery Terms and Conditions

Download ppt "Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non–small cell lung cancer: A propensity-matched analysis  Whitney S. Brandt, MD, Wanpu."

Similar presentations

A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer  Mian Xi, MD, Zhongxing.

A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer  Mian Xi, MD, Zhongxing.
A national analysis of wedge resection versus stereotactic body radiation therapy for stage IA non–small cell lung cancer  Babatunde A. Yerokun, MD, Chi-Fu.

A national analysis of wedge resection versus stereotactic body radiation therapy for stage IA non–small cell lung cancer  Babatunde A. Yerokun, MD, Chi-Fu.
Radiotherapy for Postoperative Thoracic Lymph Node Recurrence of Non–Small-Cell Lung Cancer Provides Better Outcomes If the Disease Is Asymptomatic and.

Radiotherapy for Postoperative Thoracic Lymph Node Recurrence of Non–Small-Cell Lung Cancer Provides Better Outcomes If the Disease Is Asymptomatic and.
Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT)  Neal E. Dunlap,

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT)  Neal E. Dunlap,
Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma  Arianna.

Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma  Arianna.
Characteristics and outcomes of secondary nodules identified on initial computed tomography scan for patients undergoing resection for primary non–small.

Characteristics and outcomes of secondary nodules identified on initial computed tomography scan for patients undergoing resection for primary non–small.
Local recurrence after surgery for non–small cell lung cancer: A recursive partitioning analysis of multi-institutional data  Chris R. Kelsey, MD, Kristin.

Local recurrence after surgery for non–small cell lung cancer: A recursive partitioning analysis of multi-institutional data  Chris R. Kelsey, MD, Kristin.
Radiotherapy for Postoperative Thoracic Lymph Node Recurrence of Non–Small-Cell Lung Cancer Provides Better Outcomes If the Disease Is Asymptomatic and.

Radiotherapy for Postoperative Thoracic Lymph Node Recurrence of Non–Small-Cell Lung Cancer Provides Better Outcomes If the Disease Is Asymptomatic and.
Surgical quality of wedge resection affects overall survival in patients with early stage non–small cell lung cancer  Gaurav S. Ajmani, MHS, Chi-Hsiung.

Surgical quality of wedge resection affects overall survival in patients with early stage non–small cell lung cancer  Gaurav S. Ajmani, MHS, Chi-Hsiung.
Does the method of radiologic surveillance affect survival after resection of stage I non– small cell lung cancer?  Traves D. Crabtree, MD, Varun Puri,

Does the method of radiologic surveillance affect survival after resection of stage I non– small cell lung cancer?  Traves D. Crabtree, MD, Varun Puri,
Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than.

Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than.
Prognostic significance of histologic differentiation, carcinoembryonic antigen value, and lymphovascular invasion in stage I non–small cell lung cancer 

Prognostic significance of histologic differentiation, carcinoembryonic antigen value, and lymphovascular invasion in stage I non–small cell lung cancer 
Paul J. Scheel, BS, Traves D. Crabtree, MD, Jennifer M

Paul J. Scheel, BS, Traves D. Crabtree, MD, Jennifer M
Vascular endothelial growth factor C complements the ability of positron emission tomography to predict nodal disease in lung cancer  Farhood Farjah,

Vascular endothelial growth factor C complements the ability of positron emission tomography to predict nodal disease in lung cancer  Farhood Farjah,
Impact of tumor size on outcomes after anatomic lung resection for stage 1A non–small cell lung cancer based on the current staging system  Shamus R.

Impact of tumor size on outcomes after anatomic lung resection for stage 1A non–small cell lung cancer based on the current staging system  Shamus R.
Which patients should be operated on after induction chemotherapy for N2 non–small cell lung cancer? Analysis of a 7-year experience in 175 patients 

Which patients should be operated on after induction chemotherapy for N2 non–small cell lung cancer? Analysis of a 7-year experience in 175 patients 
Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer  Hong.

Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer  Hong.
Surgery for oligometastatic non–small cell lung cancer: Long-term results from a single center experience  Maria Teresa Congedo, MD, Alfredo Cesario,

Surgery for oligometastatic non–small cell lung cancer: Long-term results from a single center experience  Maria Teresa Congedo, MD, Alfredo Cesario,
Joshua E. Rosen, BASc, Michelle C

Joshua E. Rosen, BASc, Michelle C
Centers for Disease Control “increased-risk” organ donor: Not so risky?  Francis D. Pagani, MD, PhD  The Journal of Thoracic and Cardiovascular Surgery 

Centers for Disease Control “increased-risk” organ donor: Not so risky?  Francis D. Pagani, MD, PhD  The Journal of Thoracic and Cardiovascular Surgery 

Similar presentations

Ads by Google